292 related articles for article (PubMed ID: 23948181)
1. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
2. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population.
Verim L; Timirci-Kahraman O; Akbulut H; Akbas A; Ozturk T; Turan S; Yaylim I; Ergen A; Ozturk O; Isbir T
In Vivo; 2014; 28(3):397-402. PubMed ID: 24815844
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
4. Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer.
Ceylan C; Yahşi S; Doğan S; ÖztÜrk E; Ceylan G
Ir J Med Sci; 2018 Nov; 187(4):1115-1119. PubMed ID: 29453645
[TBL] [Abstract][Full Text] [Related]
5. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer.
Ahirwar D; Kesarwani P; Manchanda PK; Mandhani A; Mittal RD
Cancer Genet Cytogenet; 2008 Jul; 184(1):1-8. PubMed ID: 18558283
[TBL] [Abstract][Full Text] [Related]
6. The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population.
Lima L; Oliveira D; Ferreira JA; Tavares A; Cruz R; Medeiros R; Santos L
BJU Int; 2015 Nov; 116(5):753-63. PubMed ID: 24931268
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Decobert M; Larue H; Bergeron A; Harel F; Pfister C; Rousseau F; Lacombe L; Fradet Y
J Urol; 2006 Apr; 175(4):1506-11. PubMed ID: 16516037
[TBL] [Abstract][Full Text] [Related]
8. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
11. IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort.
Ahirwar DK; Mandhani A; Mittal RD
Arch Med Res; 2010 Feb; 41(2):97-103. PubMed ID: 20470938
[TBL] [Abstract][Full Text] [Related]
12. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.
Ahirwar DK; Mandhani A; Dharaskar A; Kesarwani P; Mittal RD
BJU Int; 2009 Sep; 104(6):867-73. PubMed ID: 19338536
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
14. Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis.
Kobak Ş; Berdeli A
Reumatismo; 2012 Dec; 64(6):374-9. PubMed ID: 23285481
[TBL] [Abstract][Full Text] [Related]
15. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.
Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY
Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669
[TBL] [Abstract][Full Text] [Related]
18. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
19. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers.
Kim YJ; Ha YS; Kim SK; Yoon HY; Lym MS; Kim MJ; Moon SK; Choi YH; Kim WJ
Clin Cancer Res; 2010 Apr; 16(7):2131-7. PubMed ID: 20233890
[TBL] [Abstract][Full Text] [Related]
20. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
